CroiValve

Executive Summary

CroiValve is a privately held medical device company headquartered in Galway, Ireland, dedicated to addressing the unmet need in tricuspid regurgitation (TR) treatment. The company has developed the DUO™ System, a minimally invasive heart valve device designed to provide a new therapeutic option for the large population of TR patients who are often underdiagnosed and undertreated. Founded in 2019, CroiValve has progressed to the approved stage, indicating that the DUO System has received regulatory clearance (likely CE marking) and is positioned for commercial launch. The technology aims to offer a less invasive alternative to traditional open-heart surgery, potentially reducing recovery times and expanding access to care. While specific financial details are not publicly available, CroiValve's focus on a high-growth cardiovascular niche and its regulatory milestone suggest a promising trajectory. The company's competitive advantage lies in its novel valve design and delivery system, which could differentiate it from existing and pipeline TR therapies. Moving forward, CroiValve's success will hinge on clinical adoption, reimbursement, and the ability to scale manufacturing and commercialization.

Upcoming Catalysts (preview)

• Q2 2024CE Mark Approval for DUO System90% success
• H2 2024First Clinical Trial Results Publication75% success
• TBDStrategic Partnership or Distribution Agreement60% success